ArsenalBio and BMS Achieve Milestone for AB-4000 Series to Advance Next-Gen T Cell Therapies for Solid Tumors
“This milestone underscores the confidence Bristol Myers Squibb has in ArsenalBio’s programmable T cell platform and our shared vision to develop transformative cell therapies for solid tumors,” said Ken Drazan, M.D., ArsenalBio’s Chairman and CEO. “Our collaboration provides increasing opportunities to address the multifactorial challenge of treating solid tumors through programmable cell engineering. We look forward to continuing our work with Bristol Myers Squibb and progressing the AB-4000 series toward clinical development to potentially benefit patients with solid tumors.”
Share:
More News
Valerie Vanhooren, Co-Founder and CEO of Ona Therapeutics, added, “ADCs have transformed cancer treatment; however, the technology has been applied to a limited number of tumor targets. These limitations restrict the number of patients who can benefit from treatments and highlight the critical need to identify new broadly expressed tumor
“Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, today announced that the Data Safety and Monitoring Board (DSMB) has completed its first
“Patients deserve more than the currently available treatment options. TAR-200 is a groundbreaking therapy for early-stage bladder cancer, designed to deliver a sustained local release of medication directly into the bladder—right where it is needed,” said Biljana Naumovic, U.S. President, Oncology, Solid Tumor, Johnson & Johnson Innovative Medicine. “This innovation
Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, “Zurletrectinib has demonstrated outstanding efficacy and safety profile in adult, adolescent, and pediatric patients with tumors harboring NTRK fusion genes, bringing better treatment options for patients with solid tumors. The Company is expanding the scope of its solid tumor
